Novo Nordisk and Vivtex Corporation have entered into a strategic partnership aimed at advancing oral biologic medicines for obesity, diabetes, and associated metabolic conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk, with the pharmaceutical company potentially committing up to $2.1 billion in milestone payments in addition to royalties on future sales.
The collaboration seeks to leverage complementary capabilities from both organizations. Novo Nordisk brings established expertise in peptide therapeutics development, while Vivtex contributes its AI-enabled gastrointestinal screening platform designed to facilitate oral delivery of biologic drugs. Historically, many effective peptide-based treatments for metabolic diseases have required injection administration, limiting patient accessibility and convenience.
This partnership represents a significant effort to address a substantial market opportunity, as oral formulations of therapies for obesity and diabetes could potentially improve patient adherence and expand treatment adoption. The deal structure reflects the substantial value placed on Vivtex's delivery technology platform, underscoring industry recognition of the technical challenges and commercial importance of developing effective oral alternatives to injectable biologics.